Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

including notable advancements in Crispr Therapeutics AG’s pipeline and strategic partnerships. The company has shown promising progress with the Casgevy launch, evidenced by an increase in ...

The in vivo gene editing pipeline is also advancing ... in their research and potential market impact. Additionally, Crispr Therapeutics AG plans to engage with regulators regarding B-cell ...

CRSP Boasts Encouraging CRISPR-Based Pipeline Programs CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next ...

CRISPR Therapeutics' stock decline is likely influenced ... CRISPR has enough in its own pipeline to worry about and fund. I just don’t see it. There’s also been some recent speculation ...

The biotech has several other exciting candidates beyond CX112. There are some risks associated with CRISPR Therapeutics. Its pipeline programs, even CX112, could flop, for instance, a typical issue ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

Shares of CRISPR Therapeutics CRSP have lost more than ... the company is yet to record revenues from its sales. Also, a lack of pipeline updates beyond Casgevy’s approval is not sitting well ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...